Summary

Autoimmune hepatitis (AIH) is a rare form of chronic hepatitis that predominantly affects women. Although the etiology is unclear, it is commonly associated with other autoimmune conditions (e.g., thyroid disease, type 1 diabetes mellitus, celiac disease). The clinical presentation ranges from asymptomatic transaminitis to acute liver failure. Diagnosis is established based on the detection of autoantibodies (e.g., antinuclear antibodies, anti-smooth muscle antibodies) and the histologic findings of interface hepatitis on liver biopsy. Treatment consists of immunosuppressive medications such as prednisone and azathioprine. The prognosis is favorable with treatment; without treatment, patients may develop cirrhosis and liver failure.

Classification

  • Type 1 AIH (80% of cases): characteristic autoantibodies include antinuclear antibodies (ANAs), anti-smooth muscle antibodies (ASMAs) anti-soluble liver antigen antibodies (anti-SLA)
  • Type 2 AIH: characteristic autoantibodies include anti-liver-kidney microsomal-1 antibodies (anti-LKM-1), anti-liver cytosol antibodies-1 (ALC-1)

Epidemiology

  • Prevalence: 0.1–2/100,000 white adults in the US, even less so in other ethnicities [1]
  • Bimodal distribution: 10–20 years and 40–60 years [2]
    • Type 1 AIH: most common in adults
    • Type 2 AIH: most common in children
  • Sex: ♀ >
    • Type 1 AIH: (∼ 4:1) [3]
    • Type 2 AIH: (∼ 10:1)

Epidemiological data refers to the US, unless otherwise specified.

Etiology

  • Idiopathic [4]
  • AIH is commonly associated with other autoimmune conditions
    • Type 1 AIH: Hashimoto thyroiditis, Graves disease, ulcerative colitis, celiac disease, rheumatoid arthritis
    • Type 2 AIH: Hashimoto thyroiditis, type 1 diabetes mellitus, vitiligo

Clinical features

AIH has an insidious onset in most patients and its presentation varies widely, ranging from asymptomatic disease to severe symptoms or even acute liver failure.

  • Nonspecific symptoms
    • Fatigue
    • Upper abdominal pain
    • Weight loss
  • Signs of acute liver failure (∼ ⅓ of patients)
  • Signs of chronic liver disease

Diagnosis

Approach [5]

  • Consider AIH in patients with unexplained liver disease.
  • Rule out other causes of hepatitis; see “Differential diagnoses.”
  • Establish the diagnosis of AIH with laboratory studies and liver histology.
  • Consider utilizing the Autoimmune Hepatitis Diagnosis calculator to facilitate the diagnosis. [6]
  • Consult hepatology for guidance on further diagnostic testing.

The diagnosis of AIH is based on positive autoantibodies (e.g., ANA, ASMA) and histological findings of interface hepatitis on biopsy.

Initial studies [5]

Laboratory tests [7][8]

  • Liver chemistries: ↑↑↑ ALT and ↑↑ AST; , GGT, normal or ALP, and bilirubin
  • Serum antibodies
    • ANA, ASMA: combination is highly specific for type 1 AIH [7]
    • Anti-LKM-1: typically positive in type 2 AIH
  • SPEP: hypergammaglobulinemia (↑ IgG)
  • CBC: normochromic anemia, thrombocytopenia, mild leukopenia
  • Inflammatory markers: ESR

Liver biopsy [7]

  • Perform following the detection of AIH antibodies to confirm the diagnosis.
  • Histological findings:
    • Lymphoplasmacytic interface hepatitis: ongoing inflammatory process with lymphocytic infiltration, bridging or multiacinar necrosis, and fibrotic changes
    • Centrilobular perivenulitis and necrosis
    • Hepatocyte emperipolesis [7]
    • Hepatocyte rosettes
    • Bile duct changes (e.g., cholangitis, ductal injury)

Additional evaluation [5]

  • Obtain further serum antibodies to clarify diagnosis if initial antibody testing is negative.
    • ALC-1 (type 2 AIH), anti-SLA (type 1 AIH)
    • Antimitochondrial antibody: rare in AIH; may indicate AIH-PBC overlap
    • pANCA: may be present in type 1 AIH or AIH-PSC overlap
  • Screen all patients for concomitant celiac disease (with anti-tTG) and thyroid disease (with TSH).
  • Assess for other common comorbidities (e.g., rheumatoid arthritis, diabetes mellitus, inflammatory bowel disease) based on clinical suspicion.

Differential diagnoses

  • Viral hepatitis (e.g., hepatitis C)
  • Primary sclerosing cholangitis
  • Primary biliary cholangitis
  • Alcohol-associated liver disease
  • Metabolic dysfunction-associated steatohepatitis
  • Drug-induced liver injury
  • Drug-induced autoimmune-like hepatitis (DIAH)
  • Hemochromatosis
  • Wilson disease

The differential diagnoses listed here are not exhaustive.

Treatment

General principles [5][7]

  • Initiate management of acute liver failure if necessary.
  • Refer patients to a hepatologist for management.
  • Immunosuppression is the mainstay of treatment.
    • Provide age-appropriate immunizations and pretreatment counseling.
    • Prevent complications of glucocorticoid therapy.
  • Liver transplantation is indicated in patients with decompensated liver cirrhosis.

Pharmacotherapy [5]

  • Indication: active disease (i.e., elevated transaminases, elevated IgG, and/or histological disease)
  • Goals of treatment
    • Reduce symptoms.
    • Reverse liver inflammation and fibrosis.
    • Achieve remission.
  • Induction therapy
    • First line: glucocorticoids (e.g., prednisone or prednisolone) with or without azathioprine (AZA)
    • Alternatives: mycophenolate, tacrolimus, infliximab, rituximab
  • Maintenance: glucocorticoid discontinuation after gradual tapering; continue AZA.
  • Monitoring
    • Check ALT, AST, IgG levels to assess for biochemical response and remission. [5]
    • Conduct transient elastography at least 6 months after successful treatment to assess for advanced fibrosis or cirrhosis
  • Treatment withdrawal
    • Consider in patients with biochemical remission for ≥ 2 years.
    • Consider repeat liver biopsy to exclude active inflammation prior to withdrawal.
    • Relapse is common; obtain AST, ALT, and IgG levels at regular intervals. [5]

Do not use azathioprine in patients with decompensated cirrhosis or acute severe AIH (i.e., jaundice, INR > 1.5). [5]

Prognosis

  • 10-year survival rate with treatment: > 90% [9]
    • Lifelong therapy is usually required.
    • Increased risk of developing hepatocellular carcinoma (HCC): Follow-ups are recommended.
  • Type 2 AIH is associated with more severe disease, a worse response to corticosteroids, and more frequent relapses.
  • Increased risk of liver cirrhosis if left untreated

External Resources

References

  1. Muri Boberg K. "Prevalence and epidemiology of autoimmune hepatitis". Clin Liver Dis. 6(3). :635-647. (2002)
  2. Baven-Pronk MAMC, Biewenga M, van Silfhout JJ, et al. "Role of age in presentation, response to therapy and outcome of autoimmune hepatitis.". Clinical and translational gastroenterology. 9(6). :165. (2018)
  3. Czaja AJ, Donaldson PT. "Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis.". Am J Gastroenterol. 97(8). :2051-7. (2002)
  4. Hardtke-wolenski M, Fischer K, Noyan F, et al. "Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells". Hepatology. 58(2). :718-28. (2013)
  5. Mack CL, Adams D, Assis DN, et al. "Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases". Hepatology. 72(2). :671-722. (2020)
  6. Alvarez F, Berg PA, Bianchi FB, et al. "International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis". J Hepatol. 31(5). :929-938. (1999)
  7. Mieli-Vergani G, Vergani D, Czaja AJ, et al. "Autoimmune hepatitis". Nat Rev Dis Primers. 4(1). (2018)
  8. Kwo PY, Cohen SM, Lim JK. "ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries". Am J Gastroenterol. 112(1). :18-35. (2017)
  9. Roberts S, Therneau T, Czaja A. "Prognosis of histological cirrhosis in type 1 autoimmune hepatitis". Gastroenterology. 110(3). :848-857. (1996)